Alcon Valuation
Is ALC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ALC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ALC (CHF81.12) is trading below our estimate of fair value (CHF93.9)
Significantly Below Fair Value: ALC is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ALC?
Other financial metrics that can be useful for relative valuation.
What is ALC's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$45.87b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 5.2x |
Enterprise Value/EBITDA | 22.2x |
PEG Ratio | 4.6x |
Price to Earnings Ratio vs Peers
How does ALC's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 47.6x | ||
YPSN Ypsomed Holding | 69.7x | 32.3% | CHF 5.5b |
STMN Straumann Holding | 73.6x | 20.8% | CHF 18.1b |
SOON Sonova Holding | 26.3x | 9.0% | CHF 15.8b |
VBSN IVF Hartmann Holding | 20.8x | n/a | CHF 314.4m |
ALC Alcon | 43.6x | 9.5% | CHF 40.1b |
Price-To-Earnings vs Peers: ALC is good value based on its Price-To-Earnings Ratio (43.6x) compared to the peer average (47.7x).
Price to Earnings Ratio vs Industry
How does ALC's PE Ratio compare vs other companies in the European Medical Equipment Industry?
Price-To-Earnings vs Industry: ALC is expensive based on its Price-To-Earnings Ratio (43.6x) compared to the European Medical Equipment industry average (30.3x).
Price to Earnings Ratio vs Fair Ratio
What is ALC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 43.8x |
Fair PE Ratio | 40.4x |
Price-To-Earnings vs Fair Ratio: ALC is expensive based on its Price-To-Earnings Ratio (43.6x) compared to the estimated Fair Price-To-Earnings Ratio (40.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | CHF 81.98 | CHF 83.96 +2.4% | 12.0% | CHF 103.12 | CHF 60.26 | n/a | 15 |
Jul ’25 | CHF 80.18 | CHF 84.17 +5.0% | 10.3% | CHF 91.01 | CHF 61.48 | n/a | 15 |
Jun ’25 | CHF 80.34 | CHF 84.23 +4.8% | 10.2% | CHF 91.35 | CHF 61.72 | n/a | 16 |
May ’25 | CHF 71.10 | CHF 84.69 +19.1% | 9.5% | CHF 92.19 | CHF 64.16 | n/a | 16 |
Apr ’25 | CHF 74.74 | CHF 84.13 +12.6% | 10.0% | CHF 91.61 | CHF 63.76 | n/a | 16 |
Mar ’25 | CHF 76.12 | CHF 80.16 +5.3% | 11.4% | CHF 90.46 | CHF 59.22 | n/a | 16 |
Feb ’25 | CHF 64.98 | CHF 78.50 +20.8% | 9.9% | CHF 90.11 | CHF 57.44 | n/a | 15 |
Jan ’25 | CHF 65.64 | CHF 76.88 +17.1% | 11.3% | CHF 89.97 | CHF 56.26 | n/a | 12 |
Dec ’24 | CHF 65.72 | CHF 79.41 +20.8% | 9.1% | CHF 91.06 | CHF 64.51 | n/a | 14 |
Nov ’24 | CHF 65.58 | CHF 83.82 +27.8% | 8.4% | CHF 93.25 | CHF 65.97 | n/a | 13 |
Oct ’24 | CHF 70.94 | CHF 86.99 +22.6% | 6.0% | CHF 94.76 | CHF 77.68 | n/a | 12 |
Sep ’24 | CHF 73.20 | CHF 84.38 +15.3% | 6.2% | CHF 91.82 | CHF 73.49 | n/a | 13 |
Aug ’24 | CHF 74.04 | CHF 81.56 +10.2% | 7.9% | CHF 90.04 | CHF 68.76 | n/a | 12 |
Jul ’24 | CHF 74.10 | CHF 83.18 +12.2% | 6.9% | CHF 90.13 | CHF 71.87 | CHF 80.18 | 12 |
Jun ’24 | CHF 71.30 | CHF 83.18 +16.7% | 6.9% | CHF 90.13 | CHF 71.87 | CHF 80.34 | 12 |
May ’24 | CHF 64.82 | CHF 78.12 +20.5% | 9.1% | CHF 86.47 | CHF 62.61 | CHF 71.10 | 12 |
Apr ’24 | CHF 64.70 | CHF 78.86 +21.9% | 9.3% | CHF 88.21 | CHF 63.87 | CHF 74.74 | 11 |
Mar ’24 | CHF 63.54 | CHF 79.56 +25.2% | 8.9% | CHF 88.11 | CHF 63.88 | CHF 76.12 | 11 |
Feb ’24 | CHF 68.76 | CHF 76.95 +11.9% | 11.2% | CHF 85.39 | CHF 58.57 | CHF 64.98 | 11 |
Jan ’24 | CHF 63.18 | CHF 76.01 +20.3% | 11.2% | CHF 84.90 | CHF 58.94 | CHF 65.64 | 10 |
Dec ’23 | CHF 65.48 | CHF 79.53 +21.5% | 9.4% | CHF 87.44 | CHF 60.70 | CHF 65.72 | 8 |
Nov ’23 | CHF 60.70 | CHF 84.19 +38.7% | 5.1% | CHF 89.51 | CHF 74.70 | CHF 65.58 | 8 |
Oct ’23 | CHF 58.14 | CHF 81.32 +39.9% | 4.1% | CHF 86.07 | CHF 74.76 | CHF 70.94 | 8 |
Sep ’23 | CHF 64.18 | CHF 83.16 +29.6% | 4.3% | CHF 88.65 | CHF 76.30 | CHF 73.20 | 7 |
Aug ’23 | CHF 74.44 | CHF 80.47 +8.1% | 7.6% | CHF 87.71 | CHF 66.66 | CHF 74.04 | 8 |
Jul ’23 | CHF 67.42 | CHF 79.64 +18.1% | 7.6% | CHF 86.70 | CHF 65.89 | CHF 74.10 | 8 |
Analyst Forecast: Target price is less than 20% higher than the current share price.